FFO
KLRS

Fortitude Family Office’s Kalaris Therapeutics KLRS Stock Holding History

Fortitude Family Office’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-114
Closed -$658 – 2403
2026
Q1 		$658 Hold
114
– – ﹤0.01% 1628
2025
Q4 		$962 Buy
+114
New +$729 ﹤0.01% 1472

Other funds holding KLRS

BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
FCA
Fortis Capital Advisors Prairie Village, Kansas $889M AUM 36.31% 1-Year Est. Return
WAM
WealthTrust Asset Management Destin, Florida $185M AUM 26.82% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Fortitude Family Office's KLRS Position: Q2 2026 in Review

Fortitude Family Office sold out of Kalaris Therapeutics (KLRS) in Q2 2026, closing a stake of 114 shares — an estimated $658 sold.

Fortitude Family Office first reported a position in KLRS in Q4 2025 and held it in 2 quarters. The position peaked at $962 in Q4 2025. 4 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Fortitude Family Office reported no remaining Kalaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 114 Kalaris Therapeutics shares in Q2 2026, an estimated $658.
  • Fortitude Family Office first reported a position in Kalaris Therapeutics in Q4 2025 and held it in 2 quarters.
  • Fortitude Family Office's Kalaris Therapeutics position peaked at $962 in Q4 2025.
  • 4 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.